B O O K - American College of Rheumatology

INDUSTRY-SUPPORTED POST-CONFERENCE SYMPOSIA
1:00 – 4:00 pm CME-Accredited Symposium
For CME-accredited symposia, the sponsoring organization is responsible for
panning and providing CME credit.
Omni at CNN Center, Grand Ballroom (Section E)
Pulmonary Arterial Hypertension (PAH) in Connective Tissue Diseases
(CTDs): Current Concepts and Cutting-Edge Constructs in Detection,
Prognosis, and Clinical Management
Jointly sponsored by Medical Education Resources and Cornerstone Medical
Communications
Supported by an educational grant from Actelion Pharmaceuticals US, Inc.
Physician (ACCME) Accreditation Statement
This activity has been planned and implemented in accordance with the
Essential Areas and policies of the Accreditation Council for Continuing
Medical Education (ACCME) through the joint sponsorship of Medical
Education Resources (MER) and Cornerstone Medical Communications.
MER is accredited by the ACCME to provide continuing medical education
for physicians.
Credit Designation Statement
Medical Education Resources designates this educational activity for a
maximum of 2.0 AMA PRA Category 1 Credit(s). Physicians should only
claim credit commensurate with the extent of their participation in the
activity.
LEARNING OBJECTIVES:
Upon completion of this session, participants should be able to:
• Describe new insights from pulmonary hypertension registries and
their prognostic implications for patients with CTDs
• Identify effective screening programs to detect pulmonary
complications and devise specific strategies to afford earlier
identification of PAH in patients with CTDs such as scleroderma
• Delineate key components of the diagnostic algorithm for PAH,
evaluate current treatment guidelines and new clinical trial results,
and determine how these are best applied in patients with CTDs
• Assess the value of measuring patient-reported outcomes as a clinical
tool for optimizing care in patients with CTDs
1:00 – 1:30 pm
Registration and Lunch
1:30 – 1:35 pm
Welcome and Introduction
Richard M. Silver, MD; Medical University of South Carolina; Charleston, SC
1:35 – 1:55 pm
Prognosis of PAH in CTD Across the Spectrum: New Insights From the
REVEAL Registry
Lorinda Chung, MD, MS; Stanford University School of Medicine; Stanford,
CA
1:55 – 2:15 pm
Screening Programs and Earlier Identification of PAH in the Scleroderma
Setting
Eric Hachulla, MD, PhD; Université de Lille 2; Lille, France
2:15 – 2:35 pm
Optimal Treatment and Achieving Goals of PAH Management in Patients
with CTDs
Vallerie V. McLaughlin, MD, FACC, FAHA; University of Michigan Medical
School; Ann Arbor, MI
2:35 – 2:55 pm
Patient-Reported Outcomes in Clinical Practice: Tools for Optimizing Care
in the Setting of CTDs
Dinesh Khanna, MD; David Geffen School of Medicine at UCLA; Los Angeles,
CA
2:55 – 3:25 pm
Clinical Pearls from Case-based Discussion
Richard M. Silver, MD; Medical University of South Carolina; Charleston, SC
3:25 – 3:30 pm
Concluding Remarks
Vallerie V. McLaughlin, MD, FACC, FAHA; University of Michigan Medical
School; Ann Arbor, MI
1:00 – 4:00 pm CME-Accredited Symposium
For CME-accredited symposia, the sponsoring organization is responsible for
panning and providing CME credit.
Embassy Suites Hotel Atlanta at Centennial Olympic Park, Legacy
Ballroom
Understanding Osteoarthritis Today: Risk Factors, Management, and Novel
Interventions
Sponsored by Cleveland Clinic
Supported by an educational grant from Covidien-Mallinckrodt, Inc.
Physician (ACCME) Accreditation Statement
This activity has been planned and implemented in accordance with the
Essential Areas and policies of the Accreditation Council for Continuing
Medical Education (ACCME) through the sponsorship of the Cleveland
Clinic. The Cleveland Clinic Foundation Center for Continuing Education
is accredited by the ACCME to provide continuing medical education for
physicians.
Credit Designation Statement
The Cleveland Clinic Foundation Center for Continuing Education designates
this educational activity for a maximum of 2.0 AMA PRA Category 1
Credit(s). Physicians should only claim credit commensurate with the
extent of their participation in the activity.
LEARNING OBJECTIVES:
Upon completion of this session, participants should be able to:
• Identify epidemiologic changes in osteoarthritis and discuss their
impact on clinical practice
• Assess efficacy and safety data from clinical trials of DMOADs and
gauge their potential impact on clinical practice
• Discuss new and emerging pain modulators as they apply to
management of patients with osteoarthritis
• Discuss the evidence indicating that osteoarthritis may be a
potentially modifiable disease
1:00 – 2:00 pm
Registration and Lunch
2:00 – 2:10 pm
Introduction
M. Elaine Husni, MD, MPH; Cleveland Clinic; Cleveland, OH
2:10 – 2:30 pm
Changing Epidemiology of Osteoarthritis and Identifying Risk Factors for
Osteoarthritis
Roland W. Moskowitz, MD; University Hospitals Case Medical Center;
Cleveland, OH
2:30 – 2:50 pm
Therapeutic Potential of Disease-Modifying Osteoarthritis Drugs
(DMOADs) Measuring Osteoarthritis Treatment Effects
Clifton O. Bingham III, MD; Johns Hopkins University; Baltimore, MD
2:50 – 3:05 pm
Panel Discussion and Questions
All Faculty
284
2010 Program Book